Potential therapeutic uses of BDNF in neurological and psychiatric disorders

By A. Nagahara, M. Tuszynski. Nature reviews. Drug discovery, 2011

862 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Developmental Neuroscience

View Paper: https://www.semanticscholar.org/paper/1e401f33a123f4a7bf17dfb0a3ae5f70ccff09c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. D. Radecki
2. G. Tabibnia

Citations in the corpus

• Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future (2023, background): “endogenous Aβ42 monomers in nanomolar concentrations stimulated the activity of cyclic adenosine monophosphate (cAMP) responsive element-binding protein (CREB) and brainderived neurotrophic factor (BDNF), which possessed key roles in the regulation of gene expressions related to neuronal functions a”
• Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, background): “342,343 In AD, key neurotrophic factors include NGF and brain-derived neurotrophic factor (BDNF), which exert their effects through speci fi c receptors such as tropomyosin-related kinase (Trk) and p75 NTR .”
• RESILIENCE TRAINING THAT CAN CHANGE THE BRAIN (2018, background): “…function BDNF, serotonin, hippocampus, LPFC Penedo and Dahn (2005); Warburton, Nicol, and Bredin (2006); Hillman, Erickson, and Kramer (2008); Nagahara and Tuszynski (2011); Nokia et al. (2016); Byun et al. (2014) Restricting food Can slow down medical disease; can improve memory, mood,…”